Core Viewpoint - The report outlines the fundraising activities and usage of funds by Anhui Huaheng Biological Technology Co., Ltd., detailing the amounts raised, their allocation, and compliance with regulatory requirements [1][2][3]. Fundraising Overview - In 2021, the company raised a total of RMB 625.32 million by issuing 27 million shares at RMB 23.16 each, with a net amount of RMB 559.26 million after deducting issuance costs of RMB 66.06 million [1]. - As of June 30, 2025, the company reported the usage and balance of the funds raised from the 2021 IPO [2]. Fund Usage and Surplus - The company has completed the fundraising projects and decided to permanently supplement working capital with surplus funds from two projects: "5000 tons/year fermentation method for alanine technical transformation expansion project" and "alternating annual production of 25,000 tons of alanine and valine project" [3]. 2022 Fundraising Activities - In 2024, the company raised RMB 699.99 million by issuing 21,122,510 shares at RMB 33.14 each, with a net amount of RMB 683.81 million after deducting issuance costs of RMB 16.19 million [4]. - The funds from the 2022 issuance were also managed under strict regulatory compliance [5][6]. Fund Management - The company has established a fundraising management system to ensure the proper storage, approval, and usage of the raised funds, adhering to relevant laws and regulations [5]. - Specific agreements were signed with banks to ensure the funds are stored in dedicated accounts, ensuring transparency and compliance [6]. Actual Fund Usage - As of June 30, 2025, the company utilized RMB 456.93 million from the 2021 IPO funds and RMB 684.05 million from the 2022 issuance for related projects [7]. - The company has not used idle funds for temporary working capital supplementation or cash management during the reporting period [9][10]. Project Adjustments - In March 2025, the company approved the addition of new products to existing projects, including L-valine and inositol, as well as increasing production capacity for other bio-based products [11]. Compliance and Reporting - The company has complied with all relevant regulations regarding the usage and disclosure of fundraising activities, with no violations reported [13].

Fundraising Overview - The total amount raised from the initial public offering (IPO) in 2021 was RMB 62,532 million, with a net amount of RMB 55,925.88 million after deducting issuance costs of RMB 6,606.12 million [1][3] - As of June 30, 2025, the total amount of funds raised from the IPO was RMB 58,997.34 million, with various deductions leading to an actual investment amount of RMB 55,925.88 million [2][3] Fund Utilization - By June 30, 2025, the actual investment amount from the 2021 IPO was RMB 45,692.77 million, with specific allocations detailed in the report [8][9] - The company approved the use of surplus funds from the "Fermentation Method L-Alanine 5000 tons/year technical transformation and expansion project" and "Alternate annual production of 25,000 tons of L-Alanine and L-Valine project" to permanently supplement working capital [3][9] 2022 Fundraising - In 2022, the company raised RMB 699,999,981.40 through a targeted issuance of A-shares, with a net amount of RMB 68,380.91 million after deducting issuance costs of RMB 1,619.09 million [4][5] - As of June 30, 2025, the total investment from the 2022 fundraising was RMB 68,404.964 million, with specific allocations also detailed in the report [8][12] Fund Management - The company has established a fundraising management method to ensure the proper storage, approval, use, and supervision of the raised funds, adhering to relevant laws and regulations [5][9] - The company has signed tripartite and quadripartite supervision agreements with banks and securities firms to ensure compliance in the management of the raised funds [7][8] Project Updates - The company has not made any changes to the fundraising projects from both the 2021 IPO and the 2022 targeted issuance [10][11] - The company has approved the addition of products such as L-Valine and Inositol to the annual production of 50,000 tons of bio-based succinic acid and bio-based product raw material production base construction project [9][12]

【SynBioCon】 获 悉， 4月22日， 华恒生物 发布2024年年报。 2024年，公 司实现营业收入21.78亿元，同比增长12.37%；归母净利润为1.90亿元， 同比下降57.80%；基本每股收益0.82元。 华恒生物表示，营收增长主要系产品销量较去年同期增加所致， 净利润下降主要系公司经营规模扩大，相关费用较去年同期有所增加；同时，受市场 竞争加剧影响，公司缬氨酸产品价格较去年同期下降，对公司利润产生影响，公司整体利润较去年同期减少。 2024年市场缬氨酸产品价格处于历史低 位。 | | | | | 单位:元 币种:人民币 | | --- | --- | --- | --- | --- | | 主要会计数据 | 2024年 | 2023年 | 本期比上年同 | 2022年 | | | | | 期增减(%) | | | 营业收入 | 2.177.940.839.23 | 1, 938, 268, 117. 78 | 12. 37 | 1. 418, 651, 882. 92 | | 归属于上市公司 | 189, 518, 896. 19 | 449, 061, 466. 72 | -57.80 ...

声明： 因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文由作者重新编写，仅作新材料相关领域介绍，本文不构成任何投资建议！转载请注明来源！ 4月22日晚间， 华恒生物（688639） 发布2024年年报。 2024年，华恒生物实现 营业收入21.78亿元 ，同比增长12.37%； 归母净利润为1.90亿元 ，同比下降57.80%；基本每股收益0.82元。 | 主要会计数据 | 2024年 | 2023年 | 本期比上年同 | 2022年 | | --- | --- | --- | --- | --- | | | | | 期增减(%) | | | 营业收入 | 2, 177, 940, 839. 23 | 1, 938, 268, 117. 78 | 12. 37 | 1, 418, 651, 882. 92 | | 归属于上市公司 | 189, 518, 896. 19 | 449, 061, 466. 72 | -57.80 | 320, 029, 449. 81 | | 股东的净利润 | | | | | | 归属于上市公司 股东的扣除非经 | 177.240.619.67 | 438.093 ...